Skip to content

Effects of exercise training with Tirzepatide on obese soldiers

Effects of combined resistance and aerobic training with Tirzepatide on some anthropometric factors, physical fitness, cardiovascular risk factors and insulin resistance in prediabetic obese soldiers

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230804059029N1
Enrollment
58
Registered
2023-08-06
Start date
2023-08-15
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity. Overweight and obesity

Interventions

Intervention 1: Control group: Participants in the control group will continue their normal lifestyle during the study and will receive the placebo once a week. Intervention 2: Intervention group: Par

Sponsors

Artesh University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 30 Years

Inclusion criteria

Inclusion criteria: Age range from 18 to 30 years, fasting glucose level 100-125 mg/dL, BMI > 30 kg/m2, not participating in regular physical activity in the last six months, absence of cardiovascular, metabolic and endocrine diseases, and absence of consumption Drugs and alcohol

Exclusion criteria

Exclusion criteria: Lack of regular attendance in training, inflammatory and severe diseases, possible injuries, personal problems

Design outcomes

Primary

MeasureTime frame
Muscular strength. Timepoint: Pre-test and post-test. Method of measurement: Indirectly using chest press and leg press.;Insulin resistance. Timepoint: Pre-test and post-test. Method of measurement: Insulin resistance will be determined using the homeostasis model of insulin resistance assessment (HOMA-IR), after measuring fasting blood glucose (FBG) and insulin.;Lipid profile. Timepoint: Pre-test and post-test. Method of measurement: Lipid profile including triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) will be measured.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehnam Bagherzadeh-Rahmani

Hakim Sabzevari University

b.bagherzadehrahmani@gmail.com+98 11 4308 2713

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026